Insight journal - Dealtalk

Nycomed’s US Dermatology business to become an independent entity

Posted on 19 May 2011

Tags: , , , ,

Following Takeda's acquisition of Nycomed, its US dermatology subsidiary has announced it will become an independent entity.

Nycomed US has a long history of being an independent, fully integrated dermatology business, which was always outside Nycomed's core business activities.

The company, including its Fougera and PharmaDerm divisions, will retain its company headquarters in Melville, New York. The management and day-to-day operations of the group will remain unchanged, led by Steve Andrzejewski, its Chief Executive Officer. The new ownership structure will become effective with the closing of Takeda’s acquisition of Nycomed, expected in the third quarter of 2011.

See Current Agreements deal record.

See also Current Agreements Takeda-Nycomed deal record.

Steve Andrzejewski, said, "Our expertise in topical drug development, manufacturing, and commercialization has established Nycomed US as a leader in the US specialty dermatology market. This transaction will enable us to continue to invest and grow as a stand-alone specialty company, and to work directly with our investors to capitalize on the many opportunities available in the dermatology market today. Although Nycomed US made a significant contribution to Nycomed on a global basis, our product portfolio was outside Nycomed’s stated strategy and our investors believe we have a highly promising future under this separate ownership structure. For our customers and employees, there is no change to our day-to-day focus and it remains business as usual.”

Nycomed US will continue to be owned primarily by Nordic Capital Inc, Credit Suisse and Avista Capital Partners, its current private equity owners.

Steve Poile

 

Print Friendly, PDF & Email

Leave a Reply